Profile

PhD, Johns Hopkins University
MPH, University of Pittsburgh



Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Stabile LP, Egloff AM, Gibson MK, Gooding WE, Ohr J, Zhou P, Rothenberger NJ, Wang L, Geiger JL, Flaherty JT, Grandis JR, Bauman JE. IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer. Oral Oncol. 2017 Jun; 69:38-45. PMID: 28559019
     
  2. Wen Y, Li H, Zeng Y, Wen W, Pendleton KP, Lui VW, Egloff AM, Grandis JR. MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin. Oncotarget. 2016 Apr 26; 7(17):23300-11. PMID: 27004400; DOI: 10.18632/oncotarget.8188;
     
  3. Li H, Wheeler S, Park Y, Ju Z, Thomas SM, Fichera M, Egloff AM, Lui VW, Duvvuri U, Bauman JE, Mills GB, Grandis JR. Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. Mol Cancer Res. 2016 Mar; 14(3):278-86. PMID: 26685214; PMCID: PMC4794346; DOI: 10.1158/1541-7786.MCR-15-0354;
     
  4. Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston PA, McKenna A, Carter SL, Golub TR, Getz G, Mills GB, Garraway LA, Grandis JR. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2015 May; 1(2):238-44. PMID: 26181029; PMCID: PMC4557203; DOI: 10.1001/jamaoncol.2015.34;
     
  5. Wheeler SE, Egloff AM, Wang L, James CD, Hammerman PS, Grandis JR. Challenges in EGFRvIII detection in head and neck squamous cell carcinoma. PLoS One. 2015; 10(2):e0117781. PMID: 25658924; PMCID: PMC4320077; DOI: 10.1371/journal.pone.0117781;
     
  6. Fung C, Zhou P, Joyce S, Trent K, Yuan JM, Grandis JR, Weissfeld JL, Romkes M, Weeks DE, Egloff AM. Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinoma. Cancer Lett. 2015 Feb 28; 357(2):549-56. PMID: 25511740; PMCID: PMC4295492; DOI: 10.1016/j.canlet.2014.12.008;
     
  7. Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. Clin Cancer Res. 2014 Oct 1; 20(19):5041-51. PMID: 25107914; PMCID: PMC4184913; DOI: 10.1158/1078-0432.CCR-14-0051;
     
  8. Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M, Choueiri M, Coffey CS, Lippman SM, Hayes DN, Cohen EE, Grandis JR, Nguyen QT, Ideker T. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet. 2014 Sep; 46(9):939-43. PMID: 25086664; PMCID: PMC4146706; DOI: 10.1038/ng.3051;
     
  9. Kagawa S, Natsuizaka M, Whelan KA, Facompre N, Naganuma S, Ohashi S, Kinugasa H, Egloff AM, Basu D, Gimotty PA, Klein-Szanto AJ, Bass AJ, Wong KK, Diehl JA, Rustgi AK, Nakagawa H. Cellular senescence checkpoint function determines differential Notch1-dependent oncogenic and tumor-suppressor activities. Oncogene. 2015 Apr 30; 34(18):2347-59. PMID: 24931169; PMCID: PMC4268095; DOI: 10.1038/onc.2014.169;
     
  10. Choby GW, Albergotti WG, Byrd JK, Egloff AM, Johnson JT. Factors contributing to recurrence of oral cavity and laryngeal tumors and estimation of tumor age. Laryngoscope. 2014 Oct; 124(10):2297-304. PMID: 24913023; DOI: 10.1002/lary.24745;
     
Showing 10 of 45 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.



Contact for Mentoring: